{"schema_version":"secwatch.filing_event.v1","accession":"0001932393-23-000004","form_type":"8-K","ticker":"GEHC","cik":"0001932393","company_name":"GE HealthCare Technologies Inc.","filed_at":"2023-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.463145+00:00","generated_at":"2026-06-20T17:18:17.728581+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"GE HealthCare preliminary Q4 revenue ~$4.9B (+7% YoY); 2023 organic growth guidance 5-7%","bullets":["Q4 2022 revenue ~$4.9B, up ~7% YoY; organic revenue growth ~12% YoY.","Full-year 2022 revenue ~$18.3B, up ~4% YoY; organic revenue growth ~7% YoY.","Full-year 2022 adjusted EBIT above outlook; free cash flow toward low end of guidance.","2023 outlook: organic revenue growth 5-7%; adjusted EBIT margin 15.0-15.5% (up 50-100 bps).","2023 free cash flow conversion guidance of 85%+."],"urls":{"canonical":"https://secwatch.observer/filing/0001932393-23-000004","json":"https://secwatch.observer/filing/0001932393-23-000004.json","markdown":"https://secwatch.observer/filing/0001932393-23-000004.md","text":"https://secwatch.observer/filing/0001932393-23-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1932393/000193239323000004/0001932393-23-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1932393/000193239323000004/gehc-20230106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:18:17.728581+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3ce1edd9b943a721b7fc4b997ab5ca18857ec831","claim":"GE HealthCare Technologies Inc. reported fourth quarter and fiscal year ended December 31, 2022 results: revenue approximately $4.9 billion. Guidance initiated.","evidence_excerpt":"solve some of the most significant clinical challenges with our precision care strategy.” Preliminary Fourth Quarter 2022 Results Fourth quarter 2022 revenue was approximately $4.9 billion. Revenue growth for the quarter was approximately 7% year over year. Organic revenue growth* for the quarter was approximately 12% year over year. Unless stated otherwise, all","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000193239323000004/0001932393-23-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and fiscal year ended December 31, 2022"},{"label":"Revenue","value":"approximately $4.9 billion"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}